113 related articles for article (PubMed ID: 9512876)
1. Neuropeptide Y Y1 receptor antagonist (BIBP 3226) attenuates stress evoked tachycardia in conscious spontaneously hypertensive rats.
Zhang W; Lundberg JM; Thorén P
Cardiovasc Drugs Ther; 1997 Dec; 11(6):801-6. PubMed ID: 9512876
[TBL] [Abstract][Full Text] [Related]
2. Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat?
Zhao XH; Sun XY; Edvinsson L; Hedner T
J Hypertens; 1997 Jan; 15(1):19-27. PubMed ID: 9050966
[TBL] [Abstract][Full Text] [Related]
3. The effect of a neuropeptide Y antagonist, BIBP 3226, on short-term arterial pressure control in conscious unrestrained rats with congestive heart failure.
Zhang W; Lundberg JM; Thorén P
Life Sci; 1999; 65(17):1839-44. PubMed ID: 10576563
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226.
Lundberg JM; Modin A
Br J Pharmacol; 1995 Dec; 116(7):2971-82. PubMed ID: 8680732
[TBL] [Abstract][Full Text] [Related]
5. The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Br J Pharmacol; 1997 Jun; 121(3):595-603. PubMed ID: 9179405
[TBL] [Abstract][Full Text] [Related]
6. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats.
Zhao XH; Sun XY; Bergdahl A; Edvinsson L; Hedner T
J Pharm Pharmacol; 1999 Nov; 51(11):1257-65. PubMed ID: 10632083
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
8. Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226.
Gicquiaux H; Tschöpl M; Doods HN; Bucher B
Br J Pharmacol; 1996 Dec; 119(7):1313-8. PubMed ID: 8968537
[TBL] [Abstract][Full Text] [Related]
9. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock.
Qureshi NU; Dayao EK; Shirali S; Zukowska-Grojec Z; Hauser GJ
Regul Pept; 1998 Sep; 75-76():215-20. PubMed ID: 9802412
[TBL] [Abstract][Full Text] [Related]
10. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties.
Doods HN; Wieland HA; Engel W; Eberlein W; Willim KD; Entzeroth M; Wienen W; Rudolf K
Regul Pept; 1996 Aug; 65(1):71-7. PubMed ID: 8876038
[TBL] [Abstract][Full Text] [Related]
11. The NPY Y1 receptor antagonist BIBP 3226 blocks NPY induced feeding via a non-specific mechanism.
Morgan DG; Small CJ; Abusnana S; Turton M; Gunn I; Heath M; Rossi M; Goldstone AP; O'Shea D; Meeran K; Ghatei M; Smith DM; Bloom S
Regul Pept; 1998 Sep; 75-76():377-82. PubMed ID: 9802432
[TBL] [Abstract][Full Text] [Related]
12. Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors.
Zukowska-Grojec Z; Dayao EK; Karwatowska-Prokopczuk E; Hauser GJ; Doods HN
Am J Physiol; 1996 Feb; 270(2 Pt 2):H796-800. PubMed ID: 8779858
[TBL] [Abstract][Full Text] [Related]
13. Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration.
Schroeder JP; Olive F; Koenig H; Hodge CW
Alcohol Clin Exp Res; 2003 Dec; 27(12):1884-91. PubMed ID: 14691375
[TBL] [Abstract][Full Text] [Related]
14. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
15. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
[TBL] [Abstract][Full Text] [Related]
18. The Y1 antagonist BIBP 3226 inhibits potentiation of methoxamine-induced vasoconstriction by neuropeptide Y.
Bischoff A; Freund A; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 1997 Nov; 356(5):635-40. PubMed ID: 9402044
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic characterization of a novel neuropeptide Y receptor antagonist.
Tadepalli AS; Harrington WW; Hashim MA; Matthews J; Leban JJ; Spaltenstein A; Daniels AJ
J Cardiovasc Pharmacol; 1996 May; 27(5):712-8. PubMed ID: 8859942
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent hyperresponsiveness of spontaneously hypertensive rats to the pressor effects of intravenous neuropeptide Y (NPY): role of mode of peptide administration and plasma NPY-like immunoreactivity.
Miller DW; Tessel RE
J Cardiovasc Pharmacol; 1991 Nov; 18(5):647-56. PubMed ID: 1723760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
